CriticalAntifungal, triazole×Atypical antipsychotics
Updated · Methodology
Mechanism
The liver clears quetiapine mainly through the enzyme CYP3A4, which also forms and clears its active metabolite norquetiapine (quetiapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Itraconazole strongly inhibits CYP3A4 (itraconazole SmPC, AEMPS). The pair has not been studied together. Ketoconazole, another CYP3A4 inhibitor, raised the quetiapine area under the curve (AUC) 5–8-fold, and itraconazole is expected to raise quetiapine levels too (quetiapine and itraconazole SmPCs, AEMPS). With some CYP3A4 substrates, high levels during itraconazole treatment prolong the QT interval and cause ventricular arrhythmias, including torsade de pointes (itraconazole SmPC, AEMPS). QT prolongation has been reported with quetiapine after marketing, at therapeutic doses and in overdose (quetiapine SmPC, AEMPS). After itraconazole is stopped, its levels fall to almost undetectable within 7–14 days (itraconazole SmPC, AEMPS).
Symptoms
Higher quetiapine levels strengthen its known effects: drowsiness and sedation, fast heart rate and low blood pressure, including on standing up, with dizziness and a risk of falls, especially in older people (quetiapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Anticholinergic effects include dry mouth, constipation and urinary retention (quetiapine SmPC, AEMPS). Very high levels, as in overdose, can cause QT prolongation, seizures, muscle breakdown (rhabdomyolysis), respiratory depression, confusion, delirium, agitation, coma and death (quetiapine SmPC, AEMPS).
Management
The combination is contraindicated in the summaries of product characteristics (SmPC) of both drugs. Quetiapine is on the list of drugs that must not be taken with itraconazole (itraconazole SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The quetiapine SmPC itself contraindicates CYP3A4 inhibitors, including azole antifungals (quetiapine SmPC, AEMPS). Do not give quetiapine during itraconazole treatment or for 2 weeks after it ends (itraconazole SmPC, AEMPS). If orthostatic hypotension occurs during quetiapine treatment, consider a lower dose or slower titration (quetiapine SmPC, AEMPS). US labels allow the pair with a dose reduction. While the patient takes a strong CYP3A4 inhibitor such as itraconazole, reduce the quetiapine dose to one sixth of the original dose, and increase it 6-fold after the inhibitor is stopped (quetiapine label, US Food and Drug Administration, FDA). Under the US itraconazole label, monitor for quetiapine adverse reactions with this combination (itraconazole FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Sporanox (itraconazole) capsules prescribing information (2026)– Janssen Pharmaceuticals. SPORANOX (itraconazole) capsules. Prescribing information, DailyMed setid a4d555fa-787c-40fb-bb7d-b0d4f7318fd0, Contraindications and Drug Interactions table
- AEMPS: Ficha técnica: Itraconazol (nº registro 65775), sección 4.3 (2026)– AEMPS, CIMA, nº registro 65775, revisión 04/2026, sección 4.3
- FDA: Seroquel (quetiapine) prescribing information (2026)– FDA label, H2-Pharma, LLC, DailyMed setid 8ae62aaf-f8c5-417f-baac-0098369ca322, revised 04/2026, section 7
- AEMPS: Ficha técnica: Itraconazol (nº registro 59343), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59343 (Sporanox 100 mg cápsulas), revisión 07/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Quetiapina (nº registro 63054), sección 4.3 (2024)– AEMPS, CIMA, nº registro 63054 (Seroquel 25 mg comprimidos recubiertos con película, Cheplapharm), revisión 12/2024, secciones 4.3, 4.4, 4.5, 4.8 y 4.9